ID   IRAK3_HUMAN             Reviewed;         596 AA.
AC   Q9Y616; B4DQ57;
DT   09-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   08-FEB-2011, sequence version 2.
DT   12-OCT-2022, entry version 185.
DE   RecName: Full=Interleukin-1 receptor-associated kinase 3;
DE            Short=IRAK-3;
DE   AltName: Full=IL-1 receptor-associated kinase M;
DE            Short=IRAK-M;
DE   AltName: Full=Inactive IL-1 receptor-associated kinase 3 {ECO:0000305};
GN   Name=IRAK3 {ECO:0000312|EMBL:AAH57800.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD40879.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND
RP   VARIANT VAL-147.
RC   TISSUE=Peripheral blood lymphocyte;
RX   PubMed=10383454; DOI=10.1074/jbc.274.27.19403;
RA   Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z.;
RT   "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated
RT   kinase (IRAK) family.";
RL   J. Biol. Chem. 274:19403-19410(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT VAL-147.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4] {ECO:0000312|EMBL:AAH57800.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-147.
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAH57800.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INVOLVEMENT IN ASRT5, AND VARIANTS LEU-22; ALA-111; MET-134; VAL-400 AND
RP   GLN-429.
RX   PubMed=17503328; DOI=10.1086/518259;
RA   Balaci L., Spada M.C., Olla N., Sole G., Loddo L., Anedda F., Naitza S.,
RA   Zuncheddu M.A., Maschio A., Altea D., Uda M., Pilia S., Sanna S.,
RA   Masala M., Crisponi L., Fattori M., Devoto M., Doratiotto S., Rassu S.,
RA   Mereu S., Giua E., Cadeddu N.G., Atzeni R., Pelosi U., Corrias A.,
RA   Perra R., Torrazza P.L., Pirina P., Ginesu F., Marcias S., Schintu M.G.,
RA   Del Giacco G.S., Manconi P.E., Malerba G., Bisognin A., Trabetti E.,
RA   Boner A., Pescollderungg L., Pignatti P.F., Schlessinger D., Cao A.,
RA   Pilia G.;
RT   "IRAK-M is involved in the pathogenesis of early-onset persistent asthma.";
RL   Am. J. Hum. Genet. 80:1103-1114(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-467, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [7] {ECO:0007744|PDB:5UKE}
RP   STRUCTURE BY NMR OF 1-119 OF MUTANTS ASP-56 AND GLU-61, FUNCTION,
RP   INTERACTION WITH PIN1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   PHOSPHORYLATION AT SER-110, ISOMERIZATION AT 110-SER-PRO-111, MUTAGENESIS
RP   OF SER-110 AND SER-467, AND VARIANT ALA-111.
RX   PubMed=29686383; DOI=10.1038/s41467-018-03886-6;
RA   Nechama M., Kwon J., Wei S., Kyi A.T., Welner R.S., Ben-Dov I.Z.,
RA   Arredouani M.S., Asara J.M., Chen C.H., Tsai C.Y., Nelson K.F.,
RA   Kobayashi K.S., Israel E., Zhou X.Z., Nicholson L.K., Lu K.P.;
RT   "The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-
RT   induced allergic airway inflammation.";
RL   Nat. Commun. 9:1603-1603(2018).
RN   [8] {ECO:0007744|PDB:6ZIW}
RP   X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF 141-455 IN COMPLEX WITH ATP
RP   ANALOG.
RA   Mathea S., Chatterjee D., Preuss F., Kraemer A., Knapp S.;
RT   "The IRAK3 Pseudokinase Domain Bound To ATPgammaS.";
RL   Submitted (JUN-2020) to the PDB data bank.
RN   [9] {ECO:0007744|PDB:6RUU}
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 145-454, SUBUNIT, INTERACTION
RP   WITH IRAK4, ATP-BINDING, DISULFIDE BONDS, AND MUTAGENESIS OF LEU-210 AND
RP   GLU-214.
RX   PubMed=33238146; DOI=10.1016/j.str.2020.11.004;
RA   Lange S.M., Nelen M.I., Cohen P., Kulathu Y.;
RT   "Dimeric Structure of the Pseudokinase IRAK3 Suggests an Allosteric
RT   Mechanism for Negative Regulation.";
RL   Structure 29:238-251.e4(2021).
RN   [10]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-57; SER-84; VAL-147; VAL-171; LEU-288;
RP   GLN-384; THR-391 AND ASN-482.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Putative inactive protein kinase which regulates signaling
CC       downstream of immune receptors including IL1R and Toll-like receptors
CC       (PubMed:10383454, PubMed:29686383). Inhibits dissociation of IRAK1 and
CC       IRAK4 from the Toll-like receptor signaling complex by either
CC       inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the
CC       receptor complex (By similarity). Upon IL33-induced lung inflammation,
CC       positively regulates expression of IL6, CSF3, CXCL2 and CCL5 mRNAs in
CC       dendritic cells (PubMed:29686383). {ECO:0000250|UniProtKB:Q8K4B2,
CC       ECO:0000269|PubMed:10383454, ECO:0000269|PubMed:29686383}.
CC   -!- SUBUNIT: Monomer (PubMed:33238146). Homodimer; disulfide-linked
CC       (PubMed:33238146). May interact with IRAK4 (when phosphorylated)
CC       (PubMed:33238146). Interacts (when phosphorylated at Ser-110) with PIN1
CC       (via WW domain) in response to IL33-mediated (but not TLR4 ligand LPS)
CC       dendritic cell stimulation (PubMed:29686383).
CC       {ECO:0000269|PubMed:29686383, ECO:0000269|PubMed:33238146}.
CC   -!- INTERACTION:
CC       Q9Y616; Q9Y4K3: TRAF6; NbExp=3; IntAct=EBI-447690, EBI-359276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:29686383}. Nucleus
CC       {ECO:0000269|PubMed:29686383}. Note=In dendritic cells, translocates
CC       into the nucleus upon IL33 stimulation. {ECO:0000250|UniProtKB:Q8K4B2}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y616-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y616-2; Sequence=VSP_041020;
CC   -!- TISSUE SPECIFICITY: Expressed in eosinophils, dendritic cells and/or
CC       monocytes (at protein level) (PubMed:29686383). Expressed predominantly
CC       in peripheral blood lymphocytes (PubMed:10383454).
CC       {ECO:0000269|PubMed:10383454, ECO:0000269|PubMed:29686383}.
CC   -!- DOMAIN: The nucleotide binding domain binds ATP with low affinity.
CC       {ECO:0000269|PubMed:33238146}.
CC   -!- DISEASE: Asthma-related traits 5 (ASRT5) [MIM:611064]: Asthma-related
CC       traits include clinical symptoms of asthma, such as coughing, wheezing,
CC       dyspnea, bronchial hyperresponsiveness as assessed by methacholine
CC       challenge test, serum IgE levels, atopy and atopic dermatitis.
CC       {ECO:0000269|PubMed:17503328}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily. {ECO:0000305}.
CC   -!- CAUTION: Ser-293 is present instead of the conserved Asp which is
CC       expected to be an active site residue. Low level autophosphorylation
CC       activity has been reported in PubMed:10383454, while other authors
CC       describe this as an inactive kinase. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF113136; AAD40879.1; -; mRNA.
DR   EMBL; AK298645; BAG60819.1; -; mRNA.
DR   EMBL; AC078889; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC078927; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC057800; AAH57800.1; -; mRNA.
DR   EMBL; BC069388; AAH69388.1; -; mRNA.
DR   CCDS; CCDS44937.1; -. [Q9Y616-2]
DR   CCDS; CCDS8975.1; -. [Q9Y616-1]
DR   RefSeq; NP_001135995.1; NM_001142523.1. [Q9Y616-2]
DR   RefSeq; NP_009130.2; NM_007199.2. [Q9Y616-1]
DR   PDB; 5UKE; NMR; -; A=1-119.
DR   PDB; 6RUU; X-ray; 2.95 A; A/B/C=145-454.
DR   PDB; 6ZIW; X-ray; 2.18 A; I=141-455.
DR   PDBsum; 5UKE; -.
DR   PDBsum; 6RUU; -.
DR   PDBsum; 6ZIW; -.
DR   AlphaFoldDB; Q9Y616; -.
DR   SMR; Q9Y616; -.
DR   BioGRID; 116382; 28.
DR   CORUM; Q9Y616; -.
DR   IntAct; Q9Y616; 21.
DR   MINT; Q9Y616; -.
DR   STRING; 9606.ENSP00000261233; -.
DR   BindingDB; Q9Y616; -.
DR   ChEMBL; CHEMBL5081; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9Y616; -.
DR   GuidetoPHARMACOLOGY; 2044; -.
DR   iPTMnet; Q9Y616; -.
DR   PhosphoSitePlus; Q9Y616; -.
DR   BioMuta; IRAK3; -.
DR   DMDM; 322510038; -.
DR   EPD; Q9Y616; -.
DR   jPOST; Q9Y616; -.
DR   MassIVE; Q9Y616; -.
DR   PaxDb; Q9Y616; -.
DR   PeptideAtlas; Q9Y616; -.
DR   PRIDE; Q9Y616; -.
DR   ProteomicsDB; 86578; -. [Q9Y616-1]
DR   ProteomicsDB; 86579; -. [Q9Y616-2]
DR   Antibodypedia; 16652; 579 antibodies from 44 providers.
DR   DNASU; 11213; -.
DR   Ensembl; ENST00000261233.9; ENSP00000261233.4; ENSG00000090376.11. [Q9Y616-1]
DR   Ensembl; ENST00000457197.2; ENSP00000409852.2; ENSG00000090376.11. [Q9Y616-2]
DR   GeneID; 11213; -.
DR   KEGG; hsa:11213; -.
DR   MANE-Select; ENST00000261233.9; ENSP00000261233.4; NM_007199.3; NP_009130.2.
DR   UCSC; uc001sth.4; human. [Q9Y616-1]
DR   CTD; 11213; -.
DR   DisGeNET; 11213; -.
DR   GeneCards; IRAK3; -.
DR   HGNC; HGNC:17020; IRAK3.
DR   HPA; ENSG00000090376; Tissue enhanced (bone).
DR   MalaCards; IRAK3; -.
DR   MIM; 604459; gene.
DR   MIM; 611064; phenotype.
DR   neXtProt; NX_Q9Y616; -.
DR   OpenTargets; ENSG00000090376; -.
DR   PharmGKB; PA38431; -.
DR   VEuPathDB; HostDB:ENSG00000090376; -.
DR   eggNOG; KOG1187; Eukaryota.
DR   GeneTree; ENSGT00940000161222; -.
DR   HOGENOM; CLU_029530_0_0_1; -.
DR   InParanoid; Q9Y616; -.
DR   OMA; QKIPFEC; -.
DR   OrthoDB; 684563at2759; -.
DR   PhylomeDB; Q9Y616; -.
DR   TreeFam; TF328924; -.
DR   PathwayCommons; Q9Y616; -.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   SignaLink; Q9Y616; -.
DR   SIGNOR; Q9Y616; -.
DR   BioGRID-ORCS; 11213; 15 hits in 1109 CRISPR screens.
DR   ChiTaRS; IRAK3; human.
DR   GeneWiki; IRAK3; -.
DR   GenomeRNAi; 11213; -.
DR   Pharos; Q9Y616; Tchem.
DR   PRO; PR:Q9Y616; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q9Y616; protein.
DR   Bgee; ENSG00000090376; Expressed in monocyte and 159 other tissues.
DR   ExpressionAtlas; Q9Y616; baseline and differential.
DR   Genevisible; Q9Y616; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0001960; P:negative regulation of cytokine-mediated signaling pathway; IC:BHF-UCL.
DR   GO; GO:0045824; P:negative regulation of innate immune response; ISS:BHF-UCL.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IMP:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; ISS:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IMP:BHF-UCL.
DR   GO; GO:0043242; P:negative regulation of protein-containing complex disassembly; IMP:BHF-UCL.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:BHF-UCL.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:0010933; P:positive regulation of macrophage tolerance induction; ISS:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043244; P:regulation of protein-containing complex disassembly; ISS:UniProtKB.
DR   GO; GO:0043330; P:response to exogenous dsRNA; ISS:BHF-UCL.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:BHF-UCL.
DR   GO; GO:0032494; P:response to peptidoglycan; ISS:BHF-UCL.
DR   GO; GO:0009615; P:response to virus; IC:BHF-UCL.
DR   CDD; cd08796; Death_IRAK-M; 1.
DR   CDD; cd14160; PK_IRAK3; 1.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR033610; IRAK3.
DR   InterPro; IPR042747; IRAK3_death.
DR   InterPro; IPR042698; IRAK3_PK.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   PANTHER; PTHR24419:SF7; PTHR24419:SF7; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00005; DEATH; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Asthma; ATP-binding; Cytoplasm;
KW   Disulfide bond; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..596
FT                   /note="Interleukin-1 receptor-associated kinase 3"
FT                   /id="PRO_0000086033"
FT   DOMAIN          41..106
FT                   /note="Death"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00064"
FT   DOMAIN          165..452
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          560..596
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         171..179
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|Ref.8, ECO:0007744|PDB:6ZIW"
FT   BINDING         192
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|Ref.8, ECO:0007744|PDB:6ZIW"
FT   BINDING         295..298
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         311
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            110..111
FT                   /note="Cis/trans isomerization of proline peptide bond; by
FT                   PIN1; dependent on Ser-110 phosphorylation"
FT                   /evidence="ECO:0000269|PubMed:29686383"
FT   MOD_RES         110
FT                   /note="Phosphoserine; by IRAK1"
FT                   /evidence="ECO:0000269|PubMed:29686383"
FT   MOD_RES         467
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   DISULFID        202
FT                   /note="Interchain (with C-287); in linked form"
FT                   /evidence="ECO:0000269|PubMed:33238146"
FT   DISULFID        287
FT                   /note="Interchain (with C-202); in linked form"
FT                   /evidence="ECO:0000269|PubMed:33238146"
FT   VAR_SEQ         45..105
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041020"
FT   VARIANT         22
FT                   /note="P -> L (may be associated with ASRT5;
FT                   dbSNP:rs536546109)"
FT                   /evidence="ECO:0000269|PubMed:17503328"
FT                   /id="VAR_035212"
FT   VARIANT         57
FT                   /note="H -> R (in dbSNP:rs35239505)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040581"
FT   VARIANT         84
FT                   /note="G -> S (in dbSNP:rs34443407)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040582"
FT   VARIANT         111
FT                   /note="P -> A (may be associated with ASRT5; abolishes
FT                   phosphorylation of Ser-110; abolishes interaction with
FT                   PIN1; no effect on cytoplasmic localization; reduces
FT                   protein stability; dbSNP:rs373806603)"
FT                   /evidence="ECO:0000269|PubMed:17503328,
FT                   ECO:0000269|PubMed:29686383"
FT                   /id="VAR_035213"
FT   VARIANT         134
FT                   /note="V -> M (may be associated with ASRT5;
FT                   dbSNP:rs138559915)"
FT                   /evidence="ECO:0000269|PubMed:17503328"
FT                   /id="VAR_035214"
FT   VARIANT         147
FT                   /note="I -> V (in dbSNP:rs1152888)"
FT                   /evidence="ECO:0000269|PubMed:10383454,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_019812"
FT   VARIANT         171
FT                   /note="I -> V (in dbSNP:rs34682166)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040583"
FT   VARIANT         269
FT                   /note="G -> S (in dbSNP:rs35823766)"
FT                   /id="VAR_033901"
FT   VARIANT         270
FT                   /note="I -> V (in dbSNP:rs11465972)"
FT                   /id="VAR_031077"
FT   VARIANT         288
FT                   /note="S -> L (in dbSNP:rs35574245)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040584"
FT   VARIANT         384
FT                   /note="R -> Q (in dbSNP:rs34272472)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040585"
FT   VARIANT         391
FT                   /note="M -> T (in dbSNP:rs35737689)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040586"
FT   VARIANT         400
FT                   /note="L -> V (may be associated with ASRT5;
FT                   dbSNP:rs146120640)"
FT                   /evidence="ECO:0000269|PubMed:17503328"
FT                   /id="VAR_035215"
FT   VARIANT         429
FT                   /note="R -> Q (may be associated with ASRT5;
FT                   dbSNP:rs140671957)"
FT                   /evidence="ECO:0000269|PubMed:17503328"
FT                   /id="VAR_035216"
FT   VARIANT         482
FT                   /note="D -> N (in dbSNP:rs35756811)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040587"
FT   MUTAGEN         110
FT                   /note="S->A: Abolishes phosphorylation. Abolishes
FT                   interaction with PIN1. Reduces protein stability."
FT                   /evidence="ECO:0000269|PubMed:29686383"
FT   MUTAGEN         110
FT                   /note="S->E: Phosphomimic. Slight decrease in the
FT                   interaction with PIN1. Weak interaction with PIN1 in
FT                   absence of IL33-mediated dendritic cell stimulation.
FT                   Increases resistant to degradation. Localizes to the
FT                   nucleus in absence of stimulus. Does not affect
FT                   isomerization of Pro-111 peptide bond."
FT                   /evidence="ECO:0000269|PubMed:29686383"
FT   MUTAGEN         210
FT                   /note="L->E: Abolishes dimerization."
FT                   /evidence="ECO:0000269|PubMed:33238146"
FT   MUTAGEN         214
FT                   /note="E->L: Enhances dimerization."
FT                   /evidence="ECO:0000269|PubMed:33238146"
FT   MUTAGEN         467
FT                   /note="S->A: No effect on the interaction with PIN1."
FT                   /evidence="ECO:0000269|PubMed:29686383"
FT   CONFLICT        560
FT                   /note="N -> D (in Ref. 2; BAG60819)"
FT                   /evidence="ECO:0000305"
FT   STRAND          17..19
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   TURN            22..24
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           25..31
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           32..34
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   STRAND          36..39
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           43..48
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           54..61
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           68..74
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   STRAND          76..78
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           83..93
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           96..102
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   STRAND          107..109
FT                   /evidence="ECO:0007829|PDB:5UKE"
FT   HELIX           155..161
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   TURN            162..165
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           167..169
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          170..173
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          175..184
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          187..194
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           203..218
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          229..231
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           233..235
FT                   /evidence="ECO:0007829|PDB:6RUU"
FT   STRAND          238..242
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           249..253
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           256..258
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           264..281
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          285..287
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          295..301
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          307..309
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          316..318
FT                   /evidence="ECO:0007829|PDB:6RUU"
FT   HELIX           343..348
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           353..369
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   STRAND          376..379
FT                   /evidence="ECO:0007829|PDB:6RUU"
FT   HELIX           383..394
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           396..402
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           412..425
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           430..432
FT                   /evidence="ECO:0007829|PDB:6ZIW"
FT   HELIX           436..449
FT                   /evidence="ECO:0007829|PDB:6ZIW"
SQ   SEQUENCE   596 AA;  67767 MW;  D050150B7BDA5B9A CRC64;
     MAGNCGARGA LSAHTLLFDL PPALLGELCA VLDSCDGALG WRGLAERLSS SWLDVRHIEK
     YVDQGKSGTR ELLWSWAQKN KTIGDLLQVL QEMGHRRAIH LITNYGAVLS PSEKSYQEGG
     FPNILFKETA NVTVDNVLIP EHNEKGILLK SSISFQNIIE GTRNFHKDFL IGEGEIFEVY
     RVEIQNLTYA VKLFKQEKKM QCKKHWKRFL SELEVLLLFH HPNILELAAY FTETEKFCLI
     YPYMRNGTLF DRLQCVGDTA PLPWHIRIGI LIGISKAIHY LHNVQPCSVI CGSISSANIL
     LDDQFQPKLT DFAMAHFRSH LEHQSCTINM TSSSSKHLWY MPEEYIRQGK LSIKTDVYSF
     GIVIMEVLTG CRVVLDDPKH IQLRDLLREL MEKRGLDSCL SFLDKKVPPC PRNFSAKLFC
     LAGRCAATRA KLRPSMDEVL NTLESTQASL YFAEDPPTSL KSFRCPSPLF LENVPSIPVE
     DDESQNNNLL PSDEGLRIDR MTQKTPFECS QSEVMFLSLD KKPESKRNEE ACNMPSSSCE
     ESWFPKYIVP SQDLRPYKVN IDPSSEAPGH SCRSRPVESS CSSKFSWDEY EQYKKE
//
